JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

FAM83A-AS1 predicts severe development of non-small cell lung cancer and adverse postoperative prognosis of thoracotomy

  • 0Department of Respiratory and Critical Care, Shanghai Pulmonary Hospital, Shanghai, 200433, China.
Journal of Cardiothoracic Surgery +

|

January 5, 2025

|

January 5, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

High FAM83A-AS1 levels in non-small cell lung cancer (NSCLC) patients predict poor prognosis after thoracotomy. This biomarker can identify individuals at higher risk for worse postoperative outcomes, aiding clinical decisions.

Area Of Science

  • Oncology
  • Molecular Biology
  • Surgical Prognostics

Background

  • Thoracotomy is a standard treatment for non-small cell lung cancer (NSCLC), but it involves significant trauma impacting patient prognosis.
  • Identifying easily detectable indicators to predict postoperative outcomes in NSCLC patients undergoing thoracotomy is crucial.
  • FAM83A-AS1 was investigated as a potential predictor for thoracotomy effectiveness and patient prognosis.

Purpose Of The Study

  • To evaluate the correlation between FAM83A-AS1 levels and patient outcomes after thoracotomy for NSCLC.
  • To determine the significance of FAM83A-AS1 in predicting postoperative prognosis in NSCLC patients.
  • To provide a reference for improving postoperative prognosis in NSCLC patients undergoing thoracotomy.

Main Methods

  • Collection of tissue and blood samples from NSCLC patients undergoing thoracotomy.
  • Analysis of plasma FAM83A-AS1 levels using PCR.
  • Evaluation of prognostic significance using logistic regression, ROC analyses, and a six-month follow-up.

Main Results

  • FAM83A-AS1 was significantly upregulated in NSCLC and associated with severe disease progression.
  • Thoracotomy reduced FAM83A-AS1 expression and levels of tumor markers (CA50, CEA, CYFRA21-1).
  • Postoperative plasma FAM83A-AS1 levels positively correlated with tumor markers and were higher in patients with worse prognoses, identifying it as a risk factor for poor outcomes.

Conclusions

  • Elevated FAM83A-AS1 in NSCLC indicates severe disease and serves as a biomarker predicting poor prognosis after thoracotomy.
  • FAM83A-AS1 is a potential indicator for assessing patient outcomes in NSCLC.
  • This finding offers a valuable reference for improving postoperative management and prognosis.

Keywords: